Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04025567 | Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral | Phase 2 | withdrawn | Jul 19, 2019 | National Cancer Institute (NCI) | slow/insufficient accrual. | Enrollment / accrual |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | withdrawn | Aug 16, 2019 | M.D. Anderson Cancer Center | Study withdrawn by supporter | Other (stated, no rule matched) |
| NCT01760616 | Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical… | Phase 4 | terminated | Jan 4, 2013 | Qidong Gaitianli Medicines Co., Ltd | difficult to recruit patients | Enrollment / accrual |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on… | Phase 1 | terminated | Sep 8, 2017 | Weill Medical College of Cornell University | terminated due to slow accrual | Enrollment / accrual |
| NCT03079778 | Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy…(TACERT) | N/A | withdrawn | Mar 14, 2017 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Opened up a separate Clinicaltrials.gov trial form, study ID TACE | Other (stated, no rule matched) |
| NCT02580253 | Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay… | Phase 2 | withdrawn | Oct 20, 2015 | Zhejiang University | no patients enrolled | Enrollment / accrual |
| NCT02867280 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion… | Phase 3 | terminated | Aug 15, 2016 | Sun Yat-sen University | Midterm analysis showed negative results. | Other (stated, no rule matched) |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of… | Phase 2 | terminated | Apr 24, 2015 | US Oncology Research | insufficient accrual | Enrollment / accrual |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell… | Phase 1 | withdrawn | Jul 14, 2017 | National Cancer Institute (NCI) | Other - Drug Manufacturer decision to close study | Drug supply |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Phase 2 | withdrawn | Oct 22, 2019 | Abramson Cancer Center at Penn Medicine | Halozyme halted development of PEGPH20 following Phase 3 failure. | Other (stated, no rule matched) |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | Phase 1 / Phase 2 | withdrawn | Aug 15, 2013 | Mirror Biologics, Inc. | interventional radiologist suffered stroke and unable to perform RFA procedure | Other (stated, no rule matched) |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | Phase 1 / Phase 2 | withdrawn | Nov 26, 2013 | Mirror Biologics, Inc. | Study site change to Thailand | Other (stated, no rule matched) |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver… | Phase 2 | withdrawn | Nov 13, 2014 | A2 Healthcare Taiwan Corporation | At sponsor's discretion | Other (stated, no rule matched) |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT03211169 | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps… | N/A | terminated | Jul 7, 2017 | Stanford University | Inadequate enrollment | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT03408561 | Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer | N/A | withdrawn | Jan 24, 2018 | University of Southern California | No accrual | Enrollment / accrual |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post…(Panc-Durval+RT) | Phase 2 | withdrawn | Aug 31, 2016 | University of Maryland, Baltimore | Funding issues caused the study to not be opened the at local IRB | Funding |
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular… | N/A | terminated | Mar 25, 2013 | Chinese University of Hong Kong | poor case accrual | Enrollment / accrual |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar… | Phase 3 | terminated | Mar 10, 2014 | Concordia Laboratories Inc. | Accrual rate remaining too low | Enrollment / accrual |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | Washington University School of Medicine | Insufficient funding and drug supply from manufacturer | Drug supply |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer… | Phase 2 | terminated | Nov 10, 2006 | National Cancer Institute (NCI) | The study was terminated after all enrolled participants progressed. | Enrollment / accrual |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT02233595 | Evaluation of Rectal Cancer Treatment Response Using PET/MRI(Rectal PET/MRI) | — | terminated | Sep 8, 2014 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients…(DCE-MRI) | Phase 4 | terminated | Mar 7, 2013 | Guerbet | The planned number of enrolled patients was not reached. | Enrollment / accrual |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With…(ORIENTAL) | Phase 3 | terminated | Nov 4, 2011 | Taiho Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL) | Phase 3 | terminated | Mar 31, 2015 | Assistance Publique - Hôpitaux de Paris | recruitment problem | Enrollment / accrual |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or… | Phase 1 / Phase 2 | withdrawn | Dec 19, 2018 | Alan Katz | CCX872-B will not be available in sufficient quantity to conduct the study. | Other (stated, no rule matched) |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar… | Phase 2 | terminated | Nov 4, 2016 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Business Decision | Sponsor / business decision |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | Phase 2 | terminated | Apr 28, 2014 | CCTU- Cancer Theme | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 16, 2020source: clinicaltrials